Complete Genomics, a struggling DNA sequencing company in Silicon Valley, said on Monday that it had agreed to be acquired for USD 117.6 million by BGI-Shenzhen, a Chinese company that operates the world’s largest sequencing operation. The deal will need antitrust clearance, because of two key players in the DNA sequencing business in a highly capital intensive and research intensive industry, as well as clearance from a national security review by the Committee on Foreign Investment in the United States. It also requires approval from certain governmental authorities in China.
Featured News
Papa John’s Wins Final Approval for $5 Million No-Poach Settlement
Aug 18, 2026 by
CPI
Apple Revamps EU App Store Rules in Deal With Regulators
Aug 18, 2026 by
CPI
South Korean Prosecutors Raid Conglomerate Over Alleged Stock Manipulation
Aug 18, 2026 by
CPI
Andreessen Horowitz Faces Justice Department Antitrust Scrutiny Over AI Board Seats
Aug 18, 2026 by
CPI
Disney Sues FCC Over ABC Licenses Over Broadcast Regulation
Aug 18, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes